- $246.37m
- $141.34m
- 55
- 34
- 87
- 60
Annual cashflow statement for Eliem Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.55 | -20.7 | -47.5 | -45.2 | -35.1 |
| Non-Cash Items | 1.85 | 9.51 | 15.6 | 7.67 | 10.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.309 | -2.94 | -4.17 | 0.21 | 3.76 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -5.01 | -14.1 | -36.1 | -37.4 | -20.6 |
| Other Investing Cash Flow Items | 0 | 8.08 | -115 | 34.4 | 69 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0 | 8.08 | -115 | 34.4 | 69 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 26.2 | 4.92 | 177 | 0 | 0.841 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 21.2 | -0.736 | 26.4 | -3.34 | 49.5 |